Galafold migalastat regulatory update

The European Commission approved Galafold migalastat from Amicus as a long-term treatment for Fabry’s disease in patients ages >=16 who have an amenable mutation. The biotech said such mutations are found in 35-50% of Fabry’s patients. Amicus has launched the drug in Germany. The company said it would price Galafold on par with enzyme replacement therapies for Fabry’s disease but did not give a specific price. Galafold is a small molecule that enhances alpha galactosidase A activity. ...